Clinical bottom line
Novel cardiac myosin activators represent a promising therapeutic approach for patients with heart failure with reduced ejection fraction (HFrEF), targeting myocardial contractility at the molecular level. Early clinical data suggest these agents may improve cardiac reverse remodeling and functional capacity beyond standard heart failure therapies. However, evidence remains preliminary, and long-term effects on mortality and hospitalization require further validation. Clinicians should consider these agents as emerging options pending confirmatory trials and guideline integration.
What the evidence shows
Cardiac myosin activators are a new class of inotropic agents designed to enhance cardiac contractility by directly modulating the myosin-actin interaction, thereby improving systolic function without increasing intracellular calcium or myocardial oxygen demand. This mechanism distinguishes them from traditional inotropes, which often carry risks of arrhythmia and increased mortality.
Leancă et al. (2023) reviewed novel therapies for HFrEF, highlighting cardiac myosin activators as capable of inducing cardiac reverse remodeling in ischemic heart disease patients. The authors noted improvements in left ventricular ejection fraction (LVEF) and reductions in ventricular volumes, suggesting potential to modify disease progression beyond symptomatic relief.
Functional capacity, a key clinical endpoint in heart failure trials, may also benefit. Lewis et al. (2022) discussed developments in exercise capacity assessment in heart failure trials, underscoring the importance of robust functional endpoints such as peak oxygen consumption (VO2) and six-minute walk distance. While their review focused broadly on trial design, it provides context for interpreting improvements seen with myosin activators in ongoing studies.
Although mavacamten, a myosin modulator, has been primarily studied in hypertrophic cardiomyopathy (HCM), Khalil et al. (2026) conducted a meta-analysis demonstrating its efficacy in improving functional capacity in HCM patients. This supports the concept that targeted myosin modulation can translate into meaningful clinical benefits, which may extend to HFrEF populations with appropriate agents.
Caveats and uncertainty
Current evidence for cardiac myosin activators in HFrEF is largely derived from early-phase trials and mechanistic studies. Data on hard clinical outcomes such as mortality, heart failure hospitalization, and long-term safety remain limited. The heterogeneity of HFrEF etiologies and patient comorbidities may influence response to therapy, necessitating careful patient selection.
Furthermore, the experience with mavacamten in HCM, while encouraging, cannot be directly extrapolated to HFrEF due to differing pathophysiology. The potential for off-target effects, drug interactions, and optimal dosing strategies requires further elucidation.
Leancă et al. (2023) emphasized that while reverse remodeling is a favorable surrogate, it does not always predict improved survival or quality of life, underscoring the need for comprehensive outcome data. Additionally, the impact of medication titration velocity on clinical outcomes in HFrEF, as discussed by Ortiz et al. (2024), suggests that careful dose escalation may be critical to maximize benefits and minimize adverse effects with new agents.
How this may change practice
If ongoing and future phase 3 trials confirm efficacy and safety, cardiac myosin activators could become a valuable addition to the therapeutic arsenal for HFrEF, particularly for patients who remain symptomatic despite guideline-directed medical therapy. Their unique mechanism may offer an alternative to traditional inotropes with a better risk profile.
Clinicians should stay informed about emerging data and consider participation in clinical trials to help define the role of these agents. Integration into practice will require education on patient selection, monitoring parameters, and potential interactions with existing heart failure medications.
In the meantime, cardiac myosin activators remain investigational, and standard therapies including neurohormonal blockade, device therapy, and lifestyle optimization should remain the cornerstone of HFrEF management.